BioRestorative Therapies, Inc., a life sciences company focused on stem cell-based therapies, has appointed Lance Alstodt as executive vice president and chief strategy officer. In this capacity, Alstodt will be responsible for developing and refining the Company’s overall strategy and implementing investment decisions. He brings over 25 years of experience in operations, strategy and mergers & acquisitions.
Alstodt was the founder and CEO of MedVest Consulting Corporation, an advisory and capital firm focused exclusively within the healthcare sector, focusing on growth and channel strategy, strategic planning, merger and acquisition support and investor activities.
Prior to MedVest, Alstodt was a career investment banker with over 20 years of experience in healthcare investment banking, including mergers and acquisitions. In 2011, he joined Leerink Partners as Managing Director to help lead its medical technology sector. He brings significant domain experience within the orthopedic and spine specific sectors. From 2008-2011, Alstodt was a Managing Director and Head of Medical Technology at Oppenheimer & Co. From 2000-2008, he was a Managing Director in the Healthcare Group and Global M&A Group at Bank of America Merrill Lynch (“BAML”). Before BAML, Alstodt spent seven years in the Global M&A Group at J.P. Morgan Chase, where he worked extensively on acquisitions, leveraged buyouts, private and public financings, exclusive sales and general advisory assignments.